Get all your news in one place.
100's of premium titles.
One app.
Start reading
Fortune
Fortune
Ryan Hogg

Novo Nordisk missed its diversity targets last year. Its CEO paid the price

Novo Nordisk President and CEO Lars Fruergaard Jorgensen testifies before the Senate Health, Education, Labor, and Pensions Committee in the Dirksen Senate Office Building on Capitol Hill on September 24, 2024 in Washington, DC. The committee heard testimony from Jorgensen about the price of popular pharmaceuticals made by Novo Nordisk that help treat diabetes and obesity, including Wegovy and Ozempic. (Credit: Chip Somodevilla/Getty Images)

Novo Nordisk’s CEO toasted the company’s record-breaking profitability and earnings on Wednesday morning as the group behind Ozempic and Wegovy put on a brave face about its ability to fight global obesity for years to come. Despite that enthusiasm, the boss of Europe’s most valuable company will have slightly lighter pockets this year.

Novo Nordisk beat analyst expectations as it grew sales by 25% in 2024, spearheaded by continued growth for its GLP-1 weight-loss-aiding medications Ozempic and Wegovy. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.